Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:05pm, Friday, 03'rd Feb 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Mersana Therapeutics to Present at Upcoming Investor Conferences
01:00pm, Thursday, 02'nd Feb 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Mersana Therapeutics to Present at Upcoming Investor Conferences
08:00am, Thursday, 02'nd Feb 2023
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
01:00pm, Wednesday, 25'th Jan 2023 GlobeNewswire Inc.
First Immunosynthen ADC product candidate enters the clinic First Immunosynthen ADC product candidate enters the clinic
Mersana: I Like The Science, Derisking Will Come From More Proof
04:29am, Monday, 23'rd Jan 2023
Mersana has excellent ADC science. A number of big pharma have bought into the science.
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
08:16pm, Friday, 20'th Jan 2023 Benzinga
Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12.
The analyst says the topline registrational data (expected in mid-2023) from the U
Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?
07:18am, Monday, 16'th Jan 2023 Zacks Investment Research
Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest furth
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:05pm, Friday, 06'th Jan 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones
12:00pm, Friday, 06'th Jan 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates
09:05pm, Thursday, 22'nd Dec 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
06:38pm, Monday, 19'th Dec 2022 Benzinga
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Axcella H
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:05pm, Friday, 02'nd Dec 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
10:00am, Tuesday, 08'th Nov 2022 Benzinga
Gainers
Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 66.5% to settle at $29.10 on Monday amid recent reports suggesting Donald Trump could announce a 2024 presidential run this week.
Mersana Therapeutics, Inc. (MRSN) Q3 2022 Earnings Call Transcript
12:03pm, Monday, 07'th Nov 2022
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Com
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
09:48am, Monday, 07'th Nov 2022
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo
